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Porcine  circovirus  type  2 (PCV2)  is now  endemic  in every  major  pig  producing  country,  causing  PCV-
associated  disease  (PCVAD),  linked  with  large  scale  economic  losses.  Current  vaccination  strategies  are
based  on the  capsid  protein  of the  virus  and  are  reasonably  successful  in  preventing  PCVAD  but  fail
to  induce  sterile  immunity.  Additionally,  vaccinating  whole  herds  is expensive  and  time  consuming.  In
the present  study  a “proof  of concept”  vaccine  trial  was  employed  to  test  the  effectiveness  of  powdered
freeze-dried  recombinant  Saccharomyces  cerevisiae  yeast  stably  expressing  the  capsid  protein  of  PCV2b  on
its  surface  as  an  orally  applied  vaccine.  PCV2-free  pigs  were  given  3 doses  of  vaccine  or left  un-vaccinated
before  challenge  with  a deﬁned  PCV2b  strain.  Rectal  temperatures  were  measured  and  serum  and  faeces
samples  were  collected  weekly.  At  the end  of the  study,  pigs  were  euthanized,  tissue  samples  taken  and
tested  for  PCV2b  load  by  qPCR  and  immunohistochemistry.  The  peak  of  viraemia  in  sera  and  faeces  of
unvaccinated  pigs  was higher  than  that  of vaccinated  pigs.  Additionally  more  sIgA was  found  in  faeces  of
vaccinated  pigs  than  unvaccinated.  Vaccination  was associated  with  lower  serum  concentrations  of  TNF
and  IL-1  but  higher  concentrations  of IFN  and  IFN  in  comparison  to  the  unvaccinated  animals.  At the
end  of the  trial, a  higher  viral  load  was  found  in  several  lymphatic  tissues  and  the  ileum of  unvaccinated
pigs  in  comparison  to vaccinated  pigs.  The  difference  between  groups  was  especially  apparent  in  the
ileum.  The  results  presented  here  demonstrate  a possible  use for recombinant  S. cerevisiae  expressing
viral  proteins  as  an oral  vaccine  against  PCV2.  A  powdered  freeze-dried  recombinant  S. cerevisiae  used  as
an oral  vaccine  could  be  mixed  with  feed  and  may  offer  a cheap  and  less  labour  intensive  alternative  to
inoculation  with  the additional  advantage  that  no  cooling  chain  would  be required  for  vaccine  transport
and storage.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Infection of pigs with porcine circovirus type 2 (PCV2), a
on-enveloped ssDNA virus causes porcine circovirus associated
iseases (PCVAD) [1–3]. Vaccination is effective in reducing symp-
oms and increasing production parameters, but does not prevent
pread of the virus. Many commercial PCV2 vaccines are PCV2
apsid (Cap) protein subunit vaccines, which is encoded by the sec-
nd open reading frame (ORF2) [4]. Vaccines are administered by
njection which can be time consuming on large pig farms. As the
riving factor behind the development of new farm-animal vac-
ines is often the economic viability, vaccines that do not need to be
dministered individually, are cheap to produce and can be stored
∗ Corresponding author. Tel.: +44 1707 666358.
E-mail address: dwerling@rvc.ac.uk (D. Werling).
ttp://dx.doi.org/10.1016/j.vaccine.2015.10.003
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article
.0/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
without a cooling chain are an attractive option. Here, oral vaccina-
tion provides an ideal target. These are often employed to achieve
a systemic IgG as well as mucosal IgA response following anti-
gen uptake by micro-fold (M)  cells [5,6]. Vaccines administered via
the oral route cause in general less stress and associated immune-
suppression for the recipient [7], both of which are risk factor for
developing PCVAD [8,9].
Saccharomyces cerevisiae (S.c.) is commonly used to produce
recombinant proteins and has a “generally regarded as safe” (GRAS)
status. Recently, S.c. has been used as delivery system for can-
cer vaccines, resulting in humoral and cellular immune responses
[10,11]. Yeast itself possesses adjuvant like properties, activat-
ing both inﬂammatory and phagocytic receptors expressed on
APCs [12]. Our own preliminary data demonstrated that freeze-
drying of S.c. expressing PCV2 Cap protein on its surface renders it
completely non-viable (Patterson and Werling, unpublished data),
without affecting expression of the Cap protein. This has interesting
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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mplications as inactivated S.c. is no longer considered a genetically
odiﬁed organism (GMO) according Directive 2001/18/EC. Addi-
ionally, inactived yeast would not require refrigeration, cutting
own on storage costs. Previous in vivo studies have demonstrated
ome success in oral vaccination using recombinant S.c. for viral
13], parasitic [14] and bacterial infections [15] in mice. Addi-
ionally, oral vaccination of mice with S.c. secreting the PCV2 Cap
rotein, potentially resulting in VLP formation, induced Cap spe-
iﬁc antibodies [7]. The fact that PCV2 infects pigs by the oral-nasal
oute [16] led us to investigate the potential of oral vaccination of
igs with freeze-dried S.c. expressing the Cap protein of PCV2 in a
on-secreted, cell-membrane anchored form.
. Materials and methods
.1. Ethics statement
All animal studies were performed according to the regulations
nd guidance provided under the UK Home Ofﬁce Animals (Scien-
iﬁc Procedures) Act 1986, under project licence number (70/7291),
s well as regulation of the RVC Ethics and Welfare Committee.
.2. Cloning
ORF2 was ampliﬁed from a recently cloned PCV2b
train (GenBank accession number JX193799; [17]), using
orward (5′-GGTACCAATGACGTATCCA-3′) and Reverse (5′-
TCGAGAGGGTTAAGTGG-3′) primers designed to add a KpnI and
hoI restriction sites. PCR conditions were 95 ◦C for 1 min, 55 ◦C for
 min, 72 ◦C for 1 min  for 34 cycles, followed by a ﬁnal extension
t 72 ◦C for 7 min. Bands representing the ampliﬁed ORF2 were
xcised, eluted, digested and ligated into the linearised pYD1
lasmid [18] using T4 DNA ligase (Promega). The correct insert
n the resulting pYD1-ORF2 plasmid was conﬁrmed by PCR and
equencing.
.3. Production of freeze-dried Cap expressing yeast particles
Preparation of competent yeast cells and transformation with
 g of pYD1 or pYD1-ORF2 was done as described [18]. After
rowing on selective plates, one colony of EBY100-pYD1-ORF2 was
noculated into 400 mL  of YNB-CAA with 2% glucose, and incubated
or 48 h at 30 ◦C and 200 rpm. Thereafter, the contents were pel-
eted in 50 mL  Falcon tubes (Fisher) by centrifugation at 300 × g,
0 min  at RT, the resulting pellet re-suspended in YNB-CAA with
% galactose, and transferred into a 2 L Erlenmeyer conical tissue
ulture ﬂask (Fisher) ﬁlled to 1.5 L with YNB-CAA with 2% galactose.
ulture was incubated at 20 ◦C at 200 rpm for 48 h and resulting
east now expressing the PCV2b Cap protein at its surface was
ermed EBY100-pYD1-Cap. After pelleting at 300 × g for 10mins at
T, yeast pellets were re-suspended in YNB-CAA with 2% galac-
ose and 5% glycerol, and aliquots stored at −80 ◦C. Each batch of
ecombinant S.c. was tested for Cap expression by ﬂow cytometry
nd all batches showed between 50 and 60% expression. Subse-
uently, yeast was freeze-dried using a MicroModulyo Freeze Dryer
Thermo-scientiﬁc) with the following cycle conditions: −40 ◦C for
0 min  with no vacuum, −30 ◦C for 300 min  under vacuum, −10 ◦C
or 300 min  under vacuum, 20 ◦C for 420 min  under vacuum and
0 ◦C for 60 min  with no vacuum. Freeze dried yeast was powdered
sing a sterile pestle and mortar and 7 g batches were stored at
80 ◦C..4. Virus preparation for infection
The PCV2b strain used for the challenging experiments [17]
as propagated as described [2]. The titre of PCV2 was 1.5 × 1093 (2015) 6199–6205
copies per mL,  as determined by qPCR, equalling a titre of 106.05
TCID50 mL−1, analysed as described [2]. Mock samples consisted of
supernatant of uninfected cells and was PCV2 free as analysed by
qPCR.
3. Experimental design
Seventeen two week old “Babraham pigs” [19] were purchased
from The Pirbright Institute (UK). All pigs were certiﬁed free
of swine inﬂuenza strains H1N1, H1N3 and H1N5 as well as
Mycoplasma hyopneumoniae, PCV1 and PCV2. Pigs were randomly
allocated to three groups (Control (n = 5), Vaccinated (n = 6) and
Unvaccinated (n = 6)), and housed in separate rooms with con-
trolled environment, separated air-ﬂow or sewage draining, and
ad lib. access to food and water. Samples as well as rectal temper-
atures were taken from all pigs on a weekly basis, and weight was
measured at the beginning and end of the study. For the ﬁrst 3
weeks of the study, pigs were vaccinated weekly by oral adminis-
tration of 7 g of freeze dried EBY100-pYD1-Cap, suspended in 20 mL
of sterile PBS (Sigma). Unvaccinated pigs group received 3 × 20 mL
PBS instead. On the same day as the third vaccination, pigs were
inoculated intra-nasally with 7.5 × 109 PCV2 particles in 5 mL  of
media, which has been shown to result in a successful PCV2 infec-
tion [9]. Control pigs were inoculated intra-nasally with 5 mL  of
media from uninfected cells (mock). Temperature of infected pigs
was monitored daily for 7 days post infection. At the conclusion of
the study, pigs were humanly killed. Samples of tonsil, mesenteric
(MLn), inguinal (ILn), and jejunal lymph node (JLn) as well as ileum
were taken and either stored in 10% buffer formalin for microscopic
analysis or stored at −80 ◦C for subsequent nucleic acid extraction.
The study is represented in a timeline diagram in Fig. S1.
3.1. Isolation of total DNA from tissue and serum samples
Total DNA was  isolated from 25 to 50 mg  of tissue sample
collected at post-mortem using a DNeasy blood and tissue kit
(Qiagen) according to the manufacturer’s instructions. In addi-
tion, DNA was  isolated from 200 L cell-free serum collected
weekly using the QiAMPMinElute Virus spin kit (Qiagen) according
the manufacturer’s instructions. In both cases, isolated DNA was
eluted in sterile, nucleic acid-free water (Sigma–Aldrich) and DNA
concentration was  determined using an Inﬁnite 200 Nanoquant
spectrophotometer (Tecan). Eluted DNA was stored at −20 ◦C.
3.2. Quantiﬁcation of PCV2 in tissue or serum samples
The number of PCV2 copies in tissue, faeces and serum sam-
ples was determined by comparison to known concentrations of
plasmid containing the whole PCV2b genome using qPCR. Sam-
ples were measured in triplicate in a ﬁnal volume of 20 L per
well in MicroAmp Fast Optical 48-microtiter well plates (Applied
Biosystems). Each well contained 2 L DNA (standard or test
sample), 10 L 2× TaqMan Universal Master Mix II (Applied Biosys-
tems), 50 pmol primers (Forward: 5′-GCTCTYTATCGGAGGATTAC-
3′, Reverse: 5′-ATAAAAACCATTACGAWGTGATA-3′) (MWG) and
2.5 M TaqMan probe (5′FAM-CCATGCCCTGAATTTCCATATGAAAT-
3′TAMRA) (Applied Biosystems), targeting a 137 bp fragment of the
PCV2 ORF1 [20]. Standard measurements were performed in a 10-
fold serial dilution from 109 PCV2 plasmid copies to 0 copies using
a StepOne Real-time PCR machine with a StepOne software (Ver-
sion 2.2.2; both Applied Biosystems). The cycle conditions were
95 ◦C for 10 min, followed by 40 cycles of 95 ◦C for 15 s, and 55 ◦C
for 1 min. Data was analysed using either StepOne software or Excel
2010 (Microsoft). Mean Ct values were used to calculate PCV2 ORF1
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vaccinated pigs, the highest viral load was detected in week 3, and
viral load constantly declined thereafter. By week 9 of the study,
PCV2 was  undetectable in the sera of two of the vaccinated pigs.
In contrast, PCV2 viral load in sera of unvaccinated pigs showed an
Fig. 1. Mean PCV2 copy number detected in the serum of pigs in different groups
over the 12 weeks of the study. DNA was isolated from serum collected from each
pig on a weekly basis and the number of PCV2 copies was determined by qPCR
and comparison to known standards. Arrow indicates time-point of last vaccina-
tion and challenge. Signiﬁcant differences between groups are depicted by *p < 0.05;
**p < 0.01.
Fig. 2. Mean PCV2 copy number detected in the faeces of pigs in different groupsR. Patterson et al. / Va
opy number in samples, which was then divided by the original
eight of tissue or faeces in mg  or the volume of serum in L.
.3. PCV2 Cap ELISA
Sera were assayed for anti-Cap PCV2 antibodies using the PCV2
b mono blocking SERELISA kit (Synbiotics) according to the man-
facturer’s instructions. Samples were read using a SpectraMax
2  plate reader with dual reading (450 nm/630 nm;  Molecular
evices), and PCV2 antibody titre was calculated from the corrected
D values.
.4. IgA ELISA
Faeces samples taken at weekly intervals throughout the study
ere thawed at room temperature. 125–400 mg  of each sample
as placed in a separate Eppendorf tube, and 8x the volume (w/v)
f PBST with 0.001% NaN3 was added to each tube and vortexed.
amples were clariﬁed by centrifugation at 10,000 g for 10 min  at
T. Supernatants were collected and stored at −20 ◦C until ELISA.
he IgA content was determined using a Pig IgA ELISA kit (Bethyl
aboratories) according to manufacturer’s instructions. Samples
ere read at 450 nm using a SpectraMax M2  plate reader (Molec-
lar Devices) and the concentration of IgA antibodies in samples
etermined against a 4-PL standard curve.
.5. Quantiﬁcation of inﬂammatory cytokines in serum samples
Serum samples collected on a weekly basis were assayed for
NF, IL-1, IFN and IFN by cytometric bead array by Affymetrix
ioscience (Affymetrix, Vienna).
.6. Immunohistochemistry
Viral antigen labelling was determined by immunohistochem-
stry using a Cap protein speciﬁc PCV2 monoclonal antibody
Ingenasa). Brieﬂy, once tissue sections were de-waxed in xylene
nd rehydrated with graded alcohols, antigen retrieval was per-
ormed by immersion in a 0.05% protease (Streptomyces griseus,
igma, UK) with an adjusted pH of 7.8 at 37 ◦C, for 15 min. After
insing, endogenous peroxidase activity was blocked by incubation
ith 3% hydrogen peroxide in 100% methanol for 20 min. Sec-
ions were then washed with a phosphate buffered saline/0.05%
ween20 solution (PBST), followed by incubation with 25% nor-
al  goat serum in PBST for 1 h, and subsequent incubation for
8 h, 4 ◦C in a humidiﬁed chamber with the primary antibody
1:200 in Dako Antibody Diluent). After overnight incubation, sec-
ions were washed in PBST (3 × 5 min), incubated for 30 min  with
nvision+ System-HRP labelled polymer (Dako), followed by 3×
ashing. Sections were ﬁnally incubated with liquid DAB+ Sub-
trate Chromogen System (Dako) for 3 min, rinsed, counterstained
ith haematoxylin, dehydrated, mounted in DPX, covered by a cov-
rslip and examined. Sections of a study pig that developed clinical
igns of PCVAD served as positive controls and sections omitting the
rimary antibody or incubated with an isotype-matched negative
ontrol antibody (murine IgG2a; Dako) served as negative controls.
nﬂammation, lymphoid depletion and PCV2 staining of tissue sec-
ions was assessed and scored in a blinded fashion by a resident
athologist according described methods [21,22]. Each pig in the
tudy was given an IHC score which was the sum of the scores for
ll tissues with regards to PCV2 staining as well as an overall score
hich was the sum of the IHC score, the lymphoid depletion score
nd the inﬂammation score. Images were taken using an Olympus
X60 microscope at ×200 magniﬁcation with a QICAM FAST Cooled
ono 12-bit camera and Image Pro Plus 5.0 software.3 (2015) 6199–6205 6201
3.7. Statistical analysis
Analyses were performed using Instat software (Graph Pad
Software, San Diego, CA, USA). Data are expressed as average
±SEM. All samples were tested for normal distribution. Time-
dependent differences in the parameters assessed were analysed by
a repeated-measure analysis of variance. In case of signiﬁcant dif-
ferences, the Dunn multiple analysis was  used. For Figs. 1, 2 and 4,
data were log 10-transformed, re-tested for normal distribution
using a Kolmogorov–Smirnov test, and weekly values compared
using an unpaired t-test.
4. Results
4.1. Oral vaccination reduces PCV2 copy numbers in the serum
All pigs remained PCV2 free until challenge at week 2 of the
study. At week 3, PCV2 DNA was detected in the serum of all chal-
lenged pigs (Fig. 1), but not in the control group (data not shown). Inover the 12 weeks of the study. DNA was isolated from faeces samples collected
from each pig on a weekly basis and the number of PCV2 copies was determined
by  qPCR and comparison to known standards. Arrow indicates time-point of last
vaccination and challenge. Signiﬁcant differences between groups are depicted by
*p  < 0.05; **p < 0.01.
6202 R. Patterson et al. / Vaccine 3
Fig. 3. Mean PCV2 antibody titre in the serum of pigs in different groups over the
12  weeks of the study. Diluted serum samples collected from each pig on a weekly
basis were tested for the presence of anti-PCV2 antibodies by ELISA and comparison
to  known standards. Arrow indicates time-point of last vaccination and challenge.
Fig. 4. Mean IgA antibody titre in the faeces of pigs in different groups over the
12 weeks of the study. Faeces samples collected from each pig on a weekly basis
were diluted 8-fold (w/v) in PBS, 0.05% Tween 20 and supernatant containing anti-
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lodies was  harvested. The antibody concentration was determined by ELISA and
omparison to known standards. Arrow indicates time-point of last vaccination and
hallenge. Signiﬁcant differences between groups are depicted by *p < 0.05.ncrease from week 3 to week 7. It has to be mentioned that sera
f control animals remained PCV2-free until week 7 of the study
hen one pig tested positive for PCV2. By week 9 of the study, all
f the pigs in the control group tested positive for PCV2 by qPCR
ig. 5. Mean inﬂammatory cytokine levels in the serum of pigs in different groups over th
asis  was tested for the presence of TNF (A), IL-1 (B), IFN (C) and IFN (D) by cytome
ast  vaccination and challenge. Signiﬁcant differences between groups are depicted by *p3 (2015) 6199–6205
indicating a breakdown in biosecurity in the pen housing the con-
trol group (data not shown).
4.2. Oral vaccination potentially reduces viral load in faeces
Both groups challenged with PCV2 at week 2 of the study
had detectable levels of PCV2 in the faeces by week 4. The PCV2
copy number in the faeces of the vaccinated group was 3.5 × 104
copies mg−1 compared to 8.5 × 104 copies mg−1 in the unvacci-
nated group (Fig. 2). However, due to high variation between
animals of the same group this result did not reach statistical signif-
icance. By week 5 of the study, PCV2 copy number found in faeces
of the vaccinated group had reduced (Fig. 2). Faeces of the con-
trol pigs remained negative until week 7 when one animal tested
positive.
4.3. Oral vaccination does not seem to impact on serum
Cap-speciﬁc antibody concentration
We  next assessed whether differences in PCV2 Cap speciﬁc anti-
body production could be detected. With the exception of one pig
in the vaccinated group, all pigs remained Cap antibody-negative
before infection at week 2 (Fig. 3; Fig. S3A). At week 4, PCV2 Cap
antibodies were detectable in vaccinated and unvaccinated pigs
(Fig. 3). Overall, antibody titres in both groups seemed to follow
a very similar pattern (Fig. 3). Additionally, anti-PCV2 antibodies
developed between week 9 and 12 in all control pigs (Fig. S3B). The
presence of antibodies in the control pigs again conﬁrmed PCV2
infection in these animals.
4.4. Oral vaccination leads to an increased IgA antibody peak in
faeces
Faecal samples collected weekly were tested for their concentra-
tion of total sIgA. The mean sIgA levels in the faeces of unvaccinated
pigs peaked at week 4 and then rapidly declined (Fig. 4). In compari-
son, the mean sIgA levels in the vaccinated pigs showed an increase
at week 1 and peaked at week 5, and seemed to stay slightly ele-
vated for the rest of the study (Fig. 4). The sIgA peak in faeces of
e 12 weeks of the study. Diluted serum samples collected from each pig on a weekly
tric bead array and comparison to known standards. Arrow indicates time-point of
 < 0.05; **p < 0.01.
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accinated pigs was 3-fold higher and 2 weeks later compared to
he unvaccinated pigs. No sIgA was detected in faeces of control
nimals (data not shown).
.5. Oral vaccination prevents proinﬂammatory cytokine
roduction, but alters IFN response
For both pro-inﬂammatory cytokines (IL-1, TNF), a clear
ncrease in cytokine concentrations was seen in unvaccinated pigs
rom week 5 onwards, reaching its peak at week 6 before declin-
ng (Fig. 5A and B), whereas sera of vaccinated pigs remained
egative. Due to the large variation between pigs of the same
ig. 6. PCV2 copies in the mesenteric lymph node (A), jejunal lymph node (B), tonsil (C) an
t  week 12 of the study. Tissue was collected from each pig post mortem and DNA was  iso
omparison to known standards. Tissue was collected post mortem and sectioned in para
ositive (Ei) and isotype control staining (Eii) are shown. IHC scoring (F) and overall scori
ollected.3 (2015) 6199–6205 6203
group, none of the observed differences reached a level of statistical
signiﬁcance.
IFN concentration in sera of vaccinated pigs started to rise at
week 1 and peaked at week 5 of the study, before declining to base-
line levels by week 6 (Fig. 5C). In contrast, there was  a small increase
in IFN in sera of unvaccinated pigs at week 3 and 4, before IFN
level peaked at week 5 and declined thereafter (Fig. 5C). Serum IFN
concentration in the sera of vaccinated pigs started to rise three
weeks after challenge (week 5), peaked at week 7 and declined
thereafter (Fig. 5D). In contrast, IFN was  only detected at week 6
and 7 in unvaccinated pigs, and the concentration of IFN in sera of
unvaccinated pigs remained lower compared to sera of vaccinated
d ileum (D) as well as IHC scores of pigs in the vaccinated and unvaccinated groups
lated from a known mass. The number of PCV2 copies was determined by qPCR and
fﬁn after which sections were stained for the capsid protein of PCV2. Examples of
ng (G) are shown for pigs in the vaccinated and unvaccinated groups for all tissues
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igs (Fig. 5D). Neither IFN was detected in sera of control pigs (data
ot shown).
.6. Oral vaccination reduces PCV2 DNA copy number as well as
ap protein expression in tissues
PCV2 copy number in tissues of vaccinated pigs was lower in
amples taken from the MLn  (Fig. 6A), JLn (Fig. 6B), tonsils (Fig. 6C)
nd ileum (Fig. 6D), compared to the unvaccinated group. The
ifference between groups was most pronounced in the ileum
Fig. 6D), with differences varying between 2-fold to almost 10-
old higher copy number in the unvaccinated group. However,
one of these differences reached statistical signiﬁcance due to
arge variation in PCV2 copy number between animals of the same
roup.
Immunohistochemistry was performed on tissue sections to
otentially conﬁrm if qPCR for ORF1 would also be reﬂected on
he protein level for ORF2. Tissue sections were scored in a blinded
ashion for lymphoid depletion, signs of inﬂammation and PCV2
mmunolabelling according to previously described methods [21].
 representative difference in labelling between the positive and
egative staining is shown (Fig. 6Ei and Eii). The mean IHC score and
verall score for the unvaccinated group were consistently higher,
lbeit not statistically different than that of the vaccinated group
Fig. 6F and G).
. Discussion
Recombinant yeast has been used in a variety of mouse and
uman cancer as well as viral infection models [12,23–26], even
n its live form [10], resulting in a strong adjuvant effect, augment-
ng antigen presentation to MHC  class I- and class II-restricted T
ells [10].
In the present study, we assessed the potential of a powdered
reeze-dried S.c. stably expressing the PCV2 Cap protein on its sur-
ace as an oral vaccine against challenge with PCV2. Vaccinated
igs had reduced PCV2 DNA copy numbers in all samples analysed.
nterestingly however, no signiﬁcant difference for anti-PCV2 anti-
odies were seen between the two groups (Fig. 4). This result is
n-line with published data showing the absence of signiﬁcant dif-
erences in antibody titres between vaccinated and non-vaccinated
igs [27], leading to the assumption that these do not correlate
ith protection/immunity during PCV2 infection [28–30]. How-
ver, there were clear differences in sIgA production between both
roups (Fig. 5). Whereas we cannot exclude that the increase in sIgA
t the early time-point in vaccinated animals may  be a response to
he yeast particles, our combined data potentially indicate that the
ral application may  also induce a PCV2-speciﬁc IgA response.
Whereas high titres of neutralising antibodies seem to be
nversely correlated with PCV2 load [31], correlates of cellular
mmune responses are less well understood [32]. Koinig et al.
ecently described a CD4 T-cell subset that was vaccine antigen spe-
iﬁc and co-produced IFN and TNF in response to PCV2 [33]. In
he present study, pro-inﬂammatory cytokine and IFN response dif-
ered between the vaccinated and unvaccinated group. Throughout
he study, we were unable to detect TNF and IL-1 in vaccinated
nimals whereas the levels in unvaccinated animals peaked at week
 and 6 (Fig. 5A and B). These data are in line with the ﬁndings of
thers describing a TNF peak at 21 days post infection [34,35].
urthermore, the absence of TNF in the vaccinated group may  be
ue to the yeast supplementation itself as a recent study showed
ecreased serum TNF levels in mice fed S.c. and infected with
CV2 [36]. However, in contrast to our results, no difference in IL-
 between the two dietary groups were observed in this study
36].3 (2015) 6199–6205
Of interest are the different kinetics in the systemic IFN
responses in the two  different groups. In vaccinated animals, IFN
levels increased from the second week of the experiment (Fig. 5C),
with a clear increase after challenge. We  believe that the oral
vaccination already induced an IFN response, which contributed
to the reduced PCV2 replication/level of DNA and subsequently
contributed to the protection of the animals. In contrast, IFN lev-
els in the unvaccinated group started to increase after challenge
(Fig. 5C), before peaking at week 5, at the same time a rise in
pro-inﬂammatory cytokines was seen, potentially reﬂecting the
response to the replicating virus. Similarly, IFN levels in vacci-
nated animals increased earlier compared to unvaccinated animals
(Fig. 5D). For the unvaccinated group, the peak in IFN concentra-
tion correlates with the peak in the presence of IFN producing
cells in response to challenge demonstrated by others at 24 days
post infection [33]. The fact that an IFN response was seen a week
earlier in the vaccinated group may  be due to the sensitisation of the
immune system to the Cap protein expressed on the yeast surface
which has been shown to induce the development of IFN secreting
cells [37] as well as a potential positive feedback loop with IFN.
In addition to the earlier rise, the mean concentration of IFN was
also higher in the vaccinated compared to the unvaccinated group
(Fig. 5D). The presence of IFN in PCV2 infection is considered
advantageous for controlling disease with an inverse correlation
observed between IFN secreting cells and PCV2 copies [38,39].
Similar to the qPCR results for ORF1, the IHC scoring demon-
strated a reduced viral ORF2 expression in the tissues of vaccinated
pigs. This was most evident in the ileum (Fig. 6D), the site where one
would expect to ﬁnd an orally applied antigen to induce an immune
response. Our data could potentially indicate that the yeast parti-
cles are necessary to stimulate a strong enough immune response
to affect PCV2 viral replication.
Although this study was  only a proof of concept study, we
believe that yeast-particles expressing one or multiple vaccine anti-
gens on their surface could provide a new and cheap option for
mass vaccination of farm animals. The success of this vaccination
approach can further be enhanced by including molecules speciﬁ-
cally targeting yeast particles to M cells [40].
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